#CMSC16 – Ocrevus (Ocrelizumab) in PPMS Prevented Disability Progression, Lowered MRI Lesion Volume, Study Shows

Data recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting showed that Roche/Genentech’s investigational drug ocrelizumab (Ocrevus) lowered the risk of disability progression in primary progressive multiple sclerosis (PPMS), a condition for which no approved treatments exist. The study was presented during the “…

#CMSC16 – Genentech’s Ocrelizumab (Ocrevus) a Promising Therapy for Primary Progressive MS; Interview with Lead Researcher

Genentech, a member of the Roche Group, was founded more than 35 years ago and has been focused on a variety of research fields, including cancer, immunology, neurodegenerative disorders, metabolic diseases, and infectious diseases. Genentech has been committed to discovering and developing new medicines for patients with major diseases of the nervous…

Genentech to Present New Data from Phase 3 Trials of Ocrevus in MS Patients at AAN Annual Meeting

Genentech announced that it will present new data from three Phase 3 clinical trials of its experimental multiple sclerosis (MS) therapy Ocrevus (ocrelizumab) at the 68th annual meeting of the American Academy of Neurology (AAN) being held in Vancouver, Canada, from April 15–21, 2016. Additionally, results of a new endpoint for…

FDA Grants ‘Breakthrough Therapy’ Designation to Genentech’s Ocrelizumab for PPMS

Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment for primary progressive multiple sclerosis (PPMS), Breakthrough Therapy Designation based on positive Phase 3 clinical trial results showing that ocrelizumab significantly reduced disability progression and other disease activity markers compared to placebo. The FDA designation is…